The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
a Infectious Diseases Area , Hospital San Pedro, Center for Biomedical Research of La Rioja (CIBIR) , Logroño , La Rioja , Spain.
José R
JR
Blanco
b Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba , Universidad de Córdoba , Córdoba , Spain.
Antonio
A
Rivero-Juárez
D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000209:etiology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000209:etiology; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000209:etiology; D012306:Risk; D000072230:Sustained Virologic Response
D000998:Antiviral Agents
Direct acting antivirals hepatitis c; HCC development; hepatocellular carcinoma; interferon-free regimen; sustained virological response